Review Article

Classic Signaling Pathways in Alveolar Injury and Repair Involved in Sepsis-Induced ALI/ARDS: New Research Progress and Prospect

Wenli Li,1,2 Duo Li,1,2 Yuansen Chen,1,2 Halidan Abudou,1,2 Haiwang Wang,1,2 Jinxia Cai,1,2 Yiping Wang,1,2 Ziquan Liu,1,2 Yanqing Liu,1,2 and Haojun Fan1,2

1Institute of Disaster and Emergency Medicine, Tianjin University, Tianjin, China
2Wenzhou Safety (Emergency) Institute, Tianjin University, Wenzhou, China

Correspondence should be addressed to Ziquan Liu; liuziquanwj@163.com, Yanqing Liu; wglyqwglyq@163.com, and Haojun Fan; haojunfan86@163.com

Received 29 March 2022; Accepted 23 May 2022; Published 18 June 2022

Academic Editor: Pier P. Sainaghi

Copyright © 2022 Wenli Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sepsis is a common critical clinical disease with high mortality that can cause approximately 10 million deaths worldwide each year. Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a common clinical complication of sepsis, which occurs primarily as diffuse alveolar injury, hypoxemia, and respiratory distress. The mortality rate of ALI/ARDS is as high as 30%-40%, which greatly endangers human health. Due to the unclear pathogenesis of ALI/ARDS, its treatment is still a worldwide problem. At present, clinical treatment mainly relies on lung-protective ventilation, prone position ventilation, and fluid management. However, there is a lack of effective and specific treatment measures. In recent years, domestic and foreign scholars have committed to basic research on ALI/ARDS, trying to further clarify its pathogenesis and find new targets and methods for the treatment of ALI/ARDS. In this review, we summarize the signaling pathways related to alveolar injury and repair in sepsis-induced ALI/ARDS and their latest research progress. They include the NF-κB, JAK2/STAT3, mitogen-activated protein kinase (MAPK), mTOR, and Notch signaling pathways. Understanding the molecular mechanisms of these signaling pathways in sepsis-induced ALI/ARDS may provide new targets and ideas for the clinical treatment of this disease.

1. Introduction

Sepsis is a fatal organ dysfunction caused by immune dysfunction following infection of the host [1, 2]. It is a serious illness commonly encountered in clinical practice. Annually, there are approximately 48.9 million sepsis cases and 11 million sepsis-related deaths worldwide [3]. Cytokine storm during sepsis can lead to unresolvable lung inflammation and the development of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). It causes irreversible damage to the lung and high mortality. Sepsis-induced ALI/ARDS can occur as a consequence of both direct lung injury caused by lung epithelial injury and indirect lung injury caused by endothelial cell injury [4–7]. Compared with ALI/ARDS caused by other causes, sepsis-related ALI/ARDS has a higher mortality rate of 30% to 40% [7–10]. In the progression of sepsis to ALI/ARDS, cytokines can mediate the aggregation and infiltration of a large number of immune cells into lung tissue to activate intracellular signal transduction pathways and release a large number of cytokines. Inflammatory cells are constantly activated, forming a vicious cycle and ultimately resulting in a cytokine storm [11–13]. Consequently, cytokine storm is a significant factor in the progression of sepsis to ALI/ARDS. A variety of inflammatory cells are activated in this process and release a large number of inflammatory mediators. They destroy the integrity of the alveolar-capillary endothelial barrier structure, with causing neutrophil infiltration and diffuse pulmonary edema. During the process, they activate multiple intracellular signaling pathways (Figure 1). However, the exact pathogenesis of the disease is still unclear. And its treatment remains a global problem. Moreover, there
are no specific drugs available for the treatment of ALI/ARDS. In this review, we summarize the roles and mechanisms of five signaling pathways in regulating alveolar injury and repair in sepsis-induced ALI/ARDS.

2. Signaling Pathways Related to ALI/ARDS

2.1. NF-κB Pathway. NF-κB is a dimeric transcription factor in B lymphocytes. It is named for its specific binding to the B-ring enhancer of the κ light immunoglobulin chain. As a family of transcription factor proteins, NF-κB is not transcriptionally active when it binds to the NF-κB inhibitor (IκB) in the cytoplasm in a resting state. When externally stimulated, IκB kinase (IKK) is activated to detach and degrade the IκB protein from NF-κB. Then, NF-κB binds to specific target sites of DNA in the nucleus to initiate the transcription and expression of target genes, releasing interleukin 2 (IL-2), interleukin 6 (IL-6), and other inflammatory factors [14]. NF-κB pathways include classical and nonclassical pathways [15]. The common activated form of the conventional signaling channel is the dimer P65/P50. NF-κB is implicated in processes such as the inflammatory response, the host immune response, cell adhesion, growth signaling, cell proliferation, cell differentiation, and apoptotic defense. Studies have shown that the NF-κB pathway plays significant roles in a variety of inflammatory respiratory diseases, including pulmonary fibrosis, asthma, lung cancer, and obstructive pulmonary disease [16]. When the body is stimulated externally, NF-κB induces the expression of several proinflammatory cytokine genes. These proinflammatory cytokines further activate the NF-κB signaling cascade in an autocrine manner to amplify the inflammatory response [17]. For sepsis-induced ALI/ARDS, new drug therapy studies related to this pathway have shown some success. For example, butorphanol significantly reduced sepsis-induced lung tissue injury and mortality by promoting M2 macrophage polarization and inhibiting M1 macrophage polarization through the NF-κB pathway in a mouse model of sepsis-induced ALI [18]. M1 macrophages produce proinflammatory factors, such as reactive oxygen species and reactive nitrogen intermediates, as well as the cytokines tumor necrosis factor-alpha (TNF-α) and IL-6 [19, 20]. M2 macrophages are polarized and produce anti-inflammatory cytokines and other substances, such as interleukin-10 (IL-10), Mrcl (CD206), and Arginase-1 (Arg-1), which are involved in wound healing and tissue repair [20, 21]. Aspirin has been shown to treat sepsis or ARDS by inhibiting NF-κB mobilization and monocytic adherence in stimulated human endothelial cells [22, 23]. Furthermore, preactivated and catabolic-deformed platelets prevent ARDS from complicating sepsis by inhibiting inflammation associated with the NF-κB [24]. Several studies have shown that HIF-1α can activate the NF-κB pathway and increase the secretion of cytokines such as TNF-α and IL-6 in the early stages of a cytokine storm [25, 26]. In addition, dehydroxymethylepoxyquinomicin (DHMEQ) can inhibit NF-κB activation and reduce inflammatory cytokine expression [27]. As shown in Figure 2, NF-κB pathway can promote autoimmunity and inflammation when it is aberrantly activated in different cell types. Dysregulated NF-κB pathway in endothelial cells can lead to aberrant chemokine production and inflammatory cell recruitment, resulting in excessive inflammation and/or tissue damage. Drugs related to the NF-κB pathway have achieved certain results in patients with the coronavirus disease 2019 (COVID-19), such as proteasome inhibitors (VL-01, bortezomib, carfilzomib, and ixazomib), Bruton tyrosine kinase inhibitors (acalabrutinib), nucleoside analogues (remdesivir), TNF-α monoclonal antibodies.
N-acetylcysteine, and corticosteroids (dexamethasone) [28]. Thus, blocking or inhibiting the NF-κB pathway could be a therapeutic target in a sepsis-induced precursor cytokine storm (Figure 2).

2.2 JAK2/STAT3 Pathway. The JAK2/STAT3 pathway is a common pathway for multiple cytokine signaling and is widely involved in multiple biological processes including the inflammatory response and apoptosis [29–31]. Janus kinases (JAKs) include JAK1, JAK2, JAK3, and TYK2. Signal transducers and activators of transcription (STATs) include seven structurally and functionally related proteins: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 [32, 33]. The JAK2/STAT3 pathway has an immunomodulatory role similar to NF-κB pathway in cytokine storms. However, it is inconclusive whether activation of this pathway has a facilitative or inhibitory effect on ALI/ARDS. Several studies have found that the cytokine storm of COVID-19 can be alleviated by inhibiting JAK2/STAT3 pathway, and drugs related to this pathway, such as baricitinib, ruxolitinib, and tofacitinib, have been used in the clinic [34–36]. However, some studies have revealed that the JAK2/STAT3 pathway promotes lung tissue repair function during lung damage [37]. IL-6 has recently received attention due to its important role in the cytokine storm caused by COVID-19 [38]. IL-6 is a central and important marker of the cytokine storm, and its secretion triggers a cascade of amplified inflammatory responses. Several studies have shown that IL-6 activates Janus kinase and phosphorylates STAT3 downstream of it through binding to receptors on the cell membrane via the JAK-STAT pathway, thereby initiating the transcription of STAT3 target genes [39, 40]. It also plays...
an important role in sepsis-induced ALI/ARDS. Researchers identified STAT3 as a key regulatory gene and an important marker of sepsis-induced ARDS by analyzing whole-blood gene expression profiles of sepsis patients and sepsis-induced ARDS patients during the evolution of their disease [29]. Lignocaine may reduce caecum ligation and puncture-(CLP-) induced lung injury and caspase-11-dependent cellular scarring of ALI mice by reducing STAT3 phosphorylation and regulating the ratio of Tregs and IL-10 expression in lung tissues [41, 42]. In a mouse model of sepsis-induced ALI, the organism may activate the STAT pathway through IL-6 to promote the development of an inflammatory response [43]. In addition, methotrexate (MTX), an anti-inflammatory agent that inhibits the JAK2/STAT3 pathway, has been shown to ameliorate systemic inflammation and lung injury in a rat model of CLP sepsis [44]. Inhibition of STAT3 activity by the small molecule inhibitor LL12 reduces the infiltration of macrophages and inflammatory cells and protected against lipopolysaccharide-(LPS-) induced ALI [45]. Moreover, JAK2/STAT3 is also involved in the poor prognosis of ARDS patients. It has been shown that IL-6 is involved in muscle dysfunction in ARDS patients via JAK2/STAT3, FOXO3a, and atrogin-1 [46]. The regeneration of the alveolar epithelium is vital for the healing of devastating lung diseases. Recent studies have been conducted to explore the effects of the JAK2/STAT3 signaling pathway on the proliferative capacity of AT2 cells and lung repair function in lung injury. For example, high-throughput and single-cell sequencing of AT2 cells isolated from ALI mice revealed that the STAT3-BDNF-TrkB signaling axis promotes alveolar epithelial regeneration after lung injury [37]. Surface-active C protein is an important surface-active ingredient for the lung, and SPC has been found to inhibit inflammation and promote lung regeneration by reducing JAK2/STAT3 activation during lung repair [47]. Therefore, activating the JAK2-STAT3 pathway has a double effect on the progression of sepsis-induced ALI/ARDS. On the one hand, the overactivation of JAK2/STAT3 induces macrophages to secrete inflammatory factors, making the cytokine storm a cascading amplification effect. On the other hand, the JAK2/STAT3 pathway can promote the proliferation and differentiation of AT2 cells and promote the repair and regeneration of the damaged lung to inhibit the progression of ALI/ARDS (Figure 2).

2.3. Mitogen-Activated Protein Kinase (MAPK) Pathway. Mitogen-activated protein kinase (MAPK) is a kind of serine/threonine kinase widely found in eukaryotic cells that transduce cells and their nuclei by phosphorylating target proteins through a three-tiered kinase cascade pathway. The pathway is implicated in cellular proliferation, growth, apoptosis, and other processes [48, 49]. Previous studies have shown that the MAPK pathway may have an important pathogenic role in the inflammatory process associated with sepsis-induced ALI/ARDS [50–52]. Studies have shown that a variety of medications inhibit the onset of the LPS-induced inflammatory response by blocking the MAPK pathway or phosphorylation [51, 53, 54]. It has been demonstrated that the oligomeric form of surfactant protein D induces anti-inflammatory effects in M1 subtype macrophages via the calreticulin/p38 MAPK in a mouse model of ALI [55]. Another study showed that ginseng could treat LPS-induced ALI in mice by reducing lung histopathological damage, pulmonary edema, cytokines, and neutrophil aggregation. Using pathway enrichment analysis from the GO and KEGG databases, the phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) and mitogen-activated protein kinase (MAPK) pathways were considered critical for ginseng in ALI/ARDS therapy [56]. In addition, downregulation of Toll-like receptor 4 (TLR4) expression and inhibition of extracellular signal-regulated kinase (ERK)1/2 and p38 MAPK activation inhibited the inflammatory responses in LPS-induced ALI [57]. Moreover, immunomodulating nanoparticles have been found to reduce macrophage inflammation by inhibiting the reprogramming of NF-κB and p38 MAPK functions by lactic acid [58]. Blocking the p38 MAPK pathway leads to a shift from proinflammatory apoptosis to noninflammatory apoptosis in macrophages, providing a new guidance for the treatment of ALI/ARDS patients [59]. Inhibiting the JNK pathway may reduce the lung damage from sepsis by reducing apoptosis [60, 61]. In addition, DUSPs dephosphorylate MAPK to control the activity of the MAPK pathway [62]. This suggests that sepsis-induced ALI/ARDS may induce phosphorylation of JNK and p38 MAPK in lung tissue. Specific inhibitors of JNK and/or p38 MAPK may block MAPK signaling, increase serum levels of anti-inflammatory factors, and decrease serum levels of proinflammatory factors, thereby significantly improving lung histopathology and permeability (Figure 2).

2.4. mTOR Pathway. Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates many important cellular processes such as cell proliferation, translation, transcription, and autophagy. It has two large physical and functional catalytic subunits. The mTOR complex 1 (mTORC1) plays a key role in cell growth in response to nutrients. And the mTOR complex 2 (mTORC2) controls cell proliferation and survival [63]. AMPK (AMP-activated protein kinase) and TOR (target of rapamycin) pathways are interrelated and antagonistic. When cells lack energy or nutrients, the AMPK pathway is activated and inhibits cell growth. However, when cells have sufficient nutrients, the TOR pathway is activated and promotes cell growth [64]. AMPK acts as an energy receptor in the cell. When intracellular ATP levels are low, this pathway is activated and provides ATP through fatty acid oxidation and autophagy. However, when intracellular ATP levels are high, it can consume ATP by regulating processes such as gluconeogenesis, lipid, and protein synthesis. Fibroblast growth factor 21 (FGF21), as a member of the superfamily FGF, is also a key regulator of glucolipid metabolism [65]. A significant increase in serum of FGF21 levels from baseline is associated with 28-day mortality in intensive care unit (ICU) patients with sepsis and ARDS [66]. Moreover, the AMPK/mTOR pathway is a switch between anabolic and catabolic processes in the cell. Ferroptosis in sepsis-induced acute lung damage has been shown that it can be attenuated by
blocking mTOR signaling and autophagy [67]. Clara secretory cell protein (CC16), a natural anti-inflammatory factor in the lung, inhibits lung injury by activating the PI3K/AKT/mTOR/ERK1/2 pathway to promote A549 cell proliferation and inhibit LPS-induced apoptosis [68]. Circulating serum miR-92a was found to be elevated in patients with sepsis-induced ARDS, and miR-92a inhibitors inhibited LPS-induced apoptosis and inflammatory responses via the Akt/mTOR pathway [69]. Furthermore, autophagy is an important intracellular process, and reactive oxygen species (ROS) and reactive nitrogen species (RNS) are the primary intracellular signaling sensors that maintain autophagy [70]. Although the role of autophagy in ALI/ARDS has been controversial, some studies have revealed adverse effects of autophagy on lung injury [71, 72], while other studies have shown protective effects [73, 74]. A recent study showed that mesenchymal stem cell (MSC) exosomes significantly improved LPS-induced ALI by inducing autophagy [75]. In addition, increased oxidative stress downstream of autophagy was found to promote red blood cell distribution width (RDW) by reducing erythrocyte survival and releasing large numbers of premature erythrocytes into the circulation, and RDW has emerged as a new independent prognostic marker in patients with sepsis-induced ARDS [76, 77]. Thus, it is clear that the mTOR signaling pathway is mainly associated with energy metabolism and autophagy is involved in regulating various biological functions in the lung, such as the inflammatory response, DNA damage repair, apoptosis, cell proliferation, and differentiation. Therefore, autophagy plays a crucial role in maintaining the metabolic homeostasis of pulmonary tissues and the development of chronic respiratory diseases. The appearance of pulmonary fibrosis in ALI/ARDS induced by late sepsis may be closely related to this process (Figure 2).

2.5. Notch Pathway. Notch pathway is highly conserved from Drosophila to mammals and plays an important role in embryonic development. The receptor and ligand of this signaling pathway are membrane proteins associated with the control of cell proliferation/differentiation and apoptosis through cellular interactions [78]. It is known that the Notch pathway affects various immune and nonimmune cells by regulating cell proliferation and fate. Activation of the Notch signaling pathway induces activated subtype (classically activated macrophage, M1) to promote inflammation, whereas blocking it induces alternative activated macrophage (M2) to suppress inflammation [79–81]. This pathway is essential for the development of various tissues and organs. Notch dysregulation is associated with various lung diseases, especially lung cancer metastases [82–89]. The important regulatory role of Notch signaling in this disease was reported in a recent study in which midkine was found to be positively associated with sepsis-induced lung injury in peripheral blood samples from patients with sepsis and in vitro studies showed that Notch 2 was involved in midkine-induced activation of the ACE system and the release of angiotensin II, which in turn led to vascular endothelial lesions [90]. Additionally, several studies have shown that inhibition of Notch signaling can reduce the activation of M1 macrophages to suppress the inflammation of sepsis [91, 92]. Reports during the COVID-19 pandemic indicate that anti-TNF-α drugs increase MAP activity in infected macrophages and the risk of infection by inducing Notch-1 signaling and its downstream effects on IL-6 and MCL-1 [93]. In addition, regulatory dendritic cells (DCregs), the most important specialized antigen-presenting cells, play an important role in the regulation of the pulmonary immune response network, and it was found that activating Notch signaling can induce DC maturation to attenuate LPS-induced ALI in MSCs therapy for ARDS [94–96]. Moreover, Notch signaling is well studied for lung development and regeneration [97–99]. Different ligands of the Notch pathway may have different effects on type II alveolar epithelial cell (AECII) transdifferentiation: Dlk1 ligands promote the proliferation of AECIIs and inhibit cell transdifferentiation, whereas Jagged1 ligands inhibit the proliferation of AECIIs and promote transdifferentiation to type I alveolar epithelial cells (AECIs). Since AECIIs and AECIs are associated with lung damage and repair in ALI/ARDS, they can provide insight into lung regeneration in late ALI/ARDS studies [100]. As a result, the Notch signaling pathway has two roles in sepsis-induced ARDS. It may promote the inflammatory response through macrophages and inhibit the inflammatory response through DCreg activation. In addition, the Notch signaling pathway is involved in pulmonary development, which may provide ideas for treating ALI/ARDS (Figure 2).

3. Conclusions and Perspectives

In summary, multiple signaling pathways are continuously activated in sepsis-induced ALI/ARDS. This disease is mainly regulated through the inflammatory response (inflammatory cell proliferation, apoptosis, and cell polarization) and lung regeneration (AT2 cell proliferation and differentiation). Inhibiting the activation of inflammatory pathways, such as NF-κB signal transduction, and promoting the transduction of anti-inflammatory pathways, such as M2 macrophages, Treg cells, and alveolar regeneration pathways, can reduce the secretion of inflammatory factors and lung edema and promote lung regeneration to cure this disease (Figure 2). Sepsis-induced ALI/ARDS is a critical clinical illness with a highly complex pathogenesis involving multiple cytokines and signaling pathways. Due to its heterogeneity among patients, there is still no effective and specific treatment for the disease. Further research will be necessary to study specific and effective target inhibitors, which depends on the study of genes and proteins involved in the related pathways. However, the study of genes for the diagnosis of inflammatory diseases and proteomics is still in the preliminary stage. In the future, we will be able to analyze the interactions between different proteins and genes through signaling pathways to deepen our understanding of the mechanisms involved. As recent studies have shown, understanding the regulation mechanisms of multiple cellular interactions of this disease is important for the diagnosis and treatment, which can provide a theoretical basis and inspiration for the development of drugs to treat sepsis-induced ALI/ARDS. In addition, the latest
experimental research of the sepsis-induced ALI/ARDS model and clinical drug research related to the signaling pathways in ALI/ARDS patients may contribute to a better understanding of the potential of cell therapy related to signaling pathway for COVID-19.

Data Availability

The data presented in the study may be made available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by the National Key R&D Program of China (2021YFC3002202), The Scientific Research Translational Foundation of Wenzhou Safety (Emergency) Institute of Tianjin University (TJUWYY2022002), and Military Logistics Open Research Project (BLB19J006).

References

[1] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (Sepsis-3),” JAMA, vol. 315, no. 8, pp. 801–810, 2016.

[2] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and septic shock,” Lancet, vol. 392, no. 10141, pp. 75–87, 2018.

[3] K. E. Rudd, S. C. Johnson, K. M. Agha et al., “Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study,” Lancet, vol. 395, no. 10219, pp. 200–211, 2020.

[4] J. A. Englert, C. Bobba, and R. M. Baron, “Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome,” JCI Insight, vol. 4, no. 2, 2019.

[5] L. A. Huppert, M. A. Mat-thay, and L. B. Ware, “Pathogenesis of acute respiratory distress syndrome,” Seminars in Respiratory and Critical Care Medicine, vol. 40, no. 1, pp. 31–39, 2019.

[6] E. Eworsuke, J. M. Major, and L. I. Gilbert McClain, “National incidence rates for Acute Respiratory Distress Syndrome (ARDS) and ARDS cause-specific factors in the United States (2006–2014),” Journal of Critical Care, vol. 47, pp. 192–197, 2018.

[7] G. Bellani, J. G. Laffey, T. Pham et al., “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries,” JAMA, vol. 315, no. 8, pp. 788–800, 2016.

[8] M. A. Matthay, R. L. Zemans, G. A. Zimmerman et al., “Acute respiratory distress syndrome,” Nature Reviews. Disease Primers, vol. 5, no. 1, p. 18, 2019.

[9] J. Villar, J. Blanco, and R. M. Kacmarek, “Current incidence and outcome of the acute respiratory distress syndrome,” Current Opinion in Critical Care, vol. 22, no. 1, pp. 1–6, 2016.

[10] R. D. Stapleton, B. M. Wang, L. D. Hudson, G. D. Rubenfeld, E. S. Caldwell, and K. P. Steinberg, “Causes and timing of death in patients with ARDS,” Chest, vol. 128, no. 2, pp. 525–532, 2005.

[11] J. Li, X. Gong, Z. Wang et al., “Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China,” Virus Research, vol. 286, article 198043, 2020.

[12] C. Lee and W. J. Choi, “Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective,” Archives of Pharmacal Research, vol. 44, no. 1, pp. 99–116, 2021.

[13] J. S. Kim, J. Y. Lee, J. W. Yang et al., “Immunopathogenesis and treatment of cytokine storm in COVID-19,” Therapeutics, vol. 11, no. 1, pp. 316–329, 2021.

[14] D. Bhatt and S. Ghosh, “Sobre as singularidades da metafisica da moral em Schopenhauer e a significacao do fenomeno de compaiçao,” Frontiers in Immunology, vol. 5, no. 2, p. 71, 2014.

[15] K. Taniguchi and M. Karin, “NF-κB, inflammation, immunity and cancer: coming of age,” Nature Reviews. Immunology, vol. 18, no. 5, pp. 309–324, 2018.

[16] K. S. Alharbi, N. K. Fulia, S. Fuloria et al., “Nuclear factor-kappa B and its role in inflammatory lung disease,” Chemico-Biological Interactions, vol. 345, article 109568, 2021.

[17] Y. Kagoya, A. Yoshimi, K. Katoaka et al., “Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity,” The Journal of Clinical Investigation, vol. 124, no. 2, pp. 528–542, 2014.

[18] G. Luan, F. Pan, L. Bu, K. Wu, A. Wang, and X. Xu, “Butorphanol promotes macrophage phenotypic transition to inhibit inflammatory lung injury via κ receptors,” Frontiers in Immunology, vol. 12, article 692286, 2021.

[19] M. A. Bouhlel, B. Derudas, E. Rigamonti et al., “PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,” Cell Metabolism, vol. 6, no. 2, pp. 137–143, 2007.

[20] S. Arora, K. Dev, B. Agarwal, P. Das, and M. A. Syed, “Macrophages: their role, activation and polarization in pulmonary diseases,” Immunobiology, vol. 223, no. 4-5, pp. 383–396, 2018.

[21] N. Wang, H. Liang, and K. Zen, “Molecular mechanisms that influence the macrophage m1-m2 polarization balance,” Frontiers in Immunology, vol. 5, p. 614, 2014.

[22] C. Weber, W. Erl, A. Pietsch, and P. C. Weber, “Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells,” Circulation, vol. 91, no. 7, pp. 1914–1917, 1995.

[23] U. N. Das, “Combination of aspirin with essential fatty acids is superior to aspirin alone to prevent or ameliorate sepsis or ARDS,” Lipids in Health and Disease, vol. 15, no. 1, p. 206, 2016.

[24] Y. J. Day, K. H. Chen, Y. L. Chen et al., “Preactivated and dis-aggregated shape-changed platelets protected against acute respiratory distress syndrome complicated by sepsis through inflammation suppression,” Shock, vol. 46, no. 5, pp. 575–586, 2016.

[25] N. Moase, F. Fouladi, A. H. Norooznezhad, R. Yarani, A. Rahmani, and K. Mansouri, “How could perfluorocarbon affect cytokine storm and angiogenesis in coronavirus disease 2019 (COVID-19): role of hypoxia-inducible factor 1α,” Inflammation Research, vol. 70, no. 7, pp. 749–752, 2021.

[26] A. Hariharan, A. R. Hakeem, S. Radhakrishnan, M. S. Reddy, and M. Rela, “The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients,” Inflammopharmacology, vol. 29, no. 1, pp. 91–100, 2021.
[27] J. Ma, Y. Zhang, T. Sugai et al., “Inhibition of cellular and animal inflammatory disease models by NF-xB inhibitor DHMEQ,” Cells, vol. 10, no. 9, p. 2271, 2021.

[28] A. Attiq, L. J. Yao, S. Afzal, and M. A. Khan, “The tricuvirate of NF-xB, inflammation and cytokine storm in COVID-19,” International Immunopharmacology, vol. 101, article 108255, Part B, 2021.

[29] J. Zhang, Y. Luo, T. Sugai et al., “Global transcriptional regulation of STAT3- and MYC-mediated sepsis-induced ARDS,” Therapeutic Advances in Respiratory Disease, vol. 13, 2019.

[30] X. Chang, L. F. Hu, X. J. Ma, J. Yin, Y. X. Liu, and J. B. Li, “Influence of roluflamist on sepsis mice through the JAK/STAT signaling pathway,” European Review for Medical and Pharmacological Sciences, vol. 23, no. 3, pp. 1335–1341, 2019.

[31] X. Yan, X. Cheng, X. He, W. Zheng, X. Yuan, and H. Chen, “HO-1 overexpressed mesenchymal stem cells ameliorate sepsis-associated acute kidney injury by activating JAK/stat 3 pathway,” Cellular and Molecular Bioengineering, vol. 11, no. 6, pp. 509–518, 2018.

[32] B. Cai, J. P. Cai, Y. L. Luo, C. Chen, and S. Zhang, “The specific roles of JAK/STAT signaling pathway in sepsis,” Inflammation, vol. 38, no. 4, pp. 1599–1608, 2015.

[33] X. Song, C. T. Wang, and X. H. Geng, “MicroRNA-29a promotes apoptosis of monocytes by targeting STAT3 during sepsis,” Genetics and Molecular Research, vol. 14, no. 4, pp. 13746–13753, 2015.

[34] G. B. Kumar and M. M. Zhou, “Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling,” Drug discovery today, vol. 27, no. 2, pp. 390–400, 2021.

[35] S. Dhillon and S. J. Keam, “Filgotinib: first approval,” Drugs, vol. 80, no. 18, pp. 1987–1997, 2020.

[36] J. Stebbing, V. Krishnan, S. de Bono et al., “Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients,” EMBO Molecular Medicine, vol. 12, no. 8, article e12697, 2020.

[37] A. J. Paris, K. E. Hayer, J. H. Oved et al., “STAT3-BDNF-TrkB signalling promotes alveolar epithelial regeneration after lung injury,” Nature Cell Biology, vol. 22, no. 10, pp. 1197–1210, 2020.

[38] F. Zhou, T. Yu, R. Du et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” The Lancet, vol. 395, no. 10229, pp. 1054–1062, 2020.

[39] F. Schaper and S. Rose-John, “Interleukin-6: biology, signaling and strategies of blockade,” Cytokine & Growth Factor Reviews, vol. 26, no. 5, pp. 475–487, 2015.

[40] U. Billing, T. Jetka, L. Nortmann et al., “Robustness and information transfer within IL-6-induced JAK/STAT signaling,” Commun Biol, vol. 2, no. 1, p. 27, 2019.

[41] Z. T. Zhang, D. Y. Zhang, K. Xie, C. J. Wang, and F. Xu, “Luteolin activates Tregs to promote IL-10 expression and alleviating caspase-11-dependent pyroptosis in sepsis-induced lung injury,” International Immunopharmacology, vol. 99, article 107914, 2021.

[42] N. Xia, G. Chen, M. Liu et al., “Anti-inflammatory effects of luteolin on experimental autoimmune thyroiditis in mice,” Experimental and Therapeutic Medicine, vol. 12, no. 6, pp. 4049–4054, 2016.

[43] M. Severgini, S. Takahashi, L. M. Rozo et al., “Activation of the STAT pathway in acute lung injury,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 286, no. 6, pp. L1282–L1292, 2004.

[44] J. Bringu´, R. Guillamat-Prats, M. L. Martinez et al., “Methotrexate ameliorates systemic inflammation and septic associated-lung damage in a cecal ligation and puncture septic rat model,” International Journal of Molecular Sciences, vol. 22, no. 17, p. 9612, 2021.

[45] J. Zhao, H. Yu, Y. Liu et al., “Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 311, no. 5, pp. L868–L880, 2016.

[46] K. A. Radigan, T. T. Nicholson, L. C. Welch et al., “Influenza A virus infection induces muscle wasting via IL-6 regulation of the E3 ubiquitin ligase atrogin-1,” Journal of Immunology, vol. 202, no. 2, pp. 484–493, 2019.

[47] H. Jin, A. K. Ciechanowicz, A. R. Kaplan et al., “Surfactant protein C ameliorates LPS-induced ARDS by suppressing MAPK signaling pathway and protecting pulmonary endothelial glycoalyx,” International Immunopharmacology, vol. 36, pp. 51–58, 2016.

[48] T. T. Cornell, A. Fleszar, W. McHugh, N. B. Blatt, A. M. Le Vine, and T. P. Shanley, “Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 303, no. 3, pp. L251–L258, 2012.

[49] W. Fang, S. X. Cai, C. L. Wang et al., “Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats,” Molecular Medicine Reports, vol. 16, no. 6, pp. 9652–9658, 2017.

[50] Z. Cong, D. Li, Y. Tao, X. Lv, and X. Zhu, “n2A-AR antagonism by BRL-44408 maleate attenuates acute lung injury in rats with downregulation of ERK1/2, p38MAPK, and p65 pathway,” Journal of Cellular Physiology, vol. 235, no. 10, pp. 6905–6914, 2020.

[51] Y. Liu, S. Mu, X. Li, Y. Liang, L. Wang, and X. Ma, “Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions,” The Journal of Surgical Research, vol. 238, pp. 175–185, 2019.

[52] J. N. Barboza, C. Silva Maia Bezerra Filho, R. O. Silva, J. V. Medeiros, and D. P. de Sousa, “An overview on the anti-inflammatory potential and antioxidant profile of eugenol,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 3957262, 2018.

[53] D. Zhang, X. Li, Y. Hu et al., “Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination,” Biochemical Pharmacology, vol. 154, pp. 183–192, 2018.

[54] D. Li, L. Pan, X. Zhang, and Z. Jiang, “Lower oligomeric form of surfactant protein D in murine acute lung injury induces M1 subtype macrophages through calreticulin/p 38 MAPK signaling pathway,” Frontiers in Immunology, vol. 12, article 687506, 2021.

[55] Q. Ding, W. Zhu, Y. Diao et al., “Elucidation of the mechanism of action of ginseng against acute lung injury/acute respiratory distress syndrome by a network pharmacology-
based strategy,” *Frontiers in Pharmacology*, vol. 11, article 611794, 2020.

[57] A. Sivanantham, D. Pattarayan, R. Bethunaicken et al., “Tannic acid protects against experimental acute lung injury through downregulation of TLR4 and MAPK,” *Journal of Cellular Physiology*, vol. 234, no. 5, pp. 6463–6476, 2019.

[58] J. J. M. Lasola, A. L. Cottingham, B. L. Scotland et al., “Immuno-modulatory nanoparticles mitigate macrophage inflammation via inhibition of PAMP interactions and lactate-mediated functional reprogramming of NF-kB and p 38 MAPK,” *Pharmaceutics*, vol. 13, no. 11, p. 1841, 2021.

[59] D. Li, W. Ren, Z. Jiang, and L. Zhu, “Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p 38 MAPK signaling pathway in a mouse model of acute lung injury,” *Molecular Medicine Reports*, vol. 18, no. 5, pp. 4399–4409, 2018.

[60] L. Lou, D. Hu, S. Chen et al., “Protective role of JNK inhibitor SP600125 in sepsis-induced acute lung injury,” *International Journal of Clinical and Experimental Pathology*, vol. 12, no. 2, pp. 528–538, 2019.

[61] Z. Xiao, F. Xu, X. Zhu et al., “Inhibition of JNK phosphorylation by curcumin analog C66 protects LPS-induced acute lung injury,” *Drug Design, Development and Therapy*, vol. 13, pp. 4161–4171, 2019.

[62] E. M. W. Hepworth and S. D. Hinton, “Pseudophosphatases as regulators of MAPK signaling,” *International journal of molecular sciences*, vol. 22, no. 22, p. 12595, 2021.

[63] J. D. Powell and G. M. Delgoffe, “The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism,” *Immunity*, vol. 33, no. 3, pp. 301–311, 2010.

[64] A. González, M. N. Hall, S. C. Lin, and D. G. Hardie, “AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control,” *Cell Metabolism*, vol. 31, no. 3, pp. 472–492, 2020.

[65] F. M. Fisher and E. Maratos-Flier, “Understanding the physiology of FGF21,” *Annual Review of Physiology*, vol. 78, no. 1, pp. 223–241, 2016.

[66] X. Li, H. Shen, T. Zhou et al., “Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?” *Respiratory Research*, vol. 22, no. 1, p. 182, 2021.

[67] J. Li, M. Li, L. Li, J. Ma, C. Yao, and S. Yao, “Hydrogen sulfide attenuates ferroptosis and stimulates autophagy by blocking mTOR signaling in sepsis-induced acute lung injury,” *Molecular Immunology*, vol. 141, pp. 318–327, 2022.

[68] J. Lin, J. Li, M. Shu et al., “The rCC16 protein protects against LPS-induced cell apoptosis and inflammatory responses in human lung pneumocytes,” *Frontiers in Pharmacology*, vol. 11, p. 1060, 2020.

[69] F. Xu, J. Yuan, S. Tian, Y. Chen, and F. Zhou, “MicroRNA-92a serves as a risk factor in sepsis-induced ARDS and regulates apoptosis and cell migration in lipopolysaccharide-induced HPMEC and A549 cell injury,” *Life Sciences*, vol. 256, article 117957, 2020.

[70] G. Filomeni, D. De Zio, and F. Cecconi, “Oxidative stress and autophagy: the clash between damage and metabolic needs,” *Cell Death and Differentiation*, vol. 22, no. 3, pp. 377–388, 2015.

[71] Y. Zhang, G. Liu, R. O. Dull, D. E. Schwartz, and G. Hu, “Autophagy in pulmonary macrophages mediates lung inflammatory injury via NLRP3 inflammasome activation during mechanical ventilation,” *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 307, no. 2, pp. L173–L185, 2014.

[72] K. Mizumura, S. M. Cloonan, J. A. Haspel, and A. M. K. Choi, “The emerging importance of autophagy in pulmonary diseases,” *Chest*, vol. 142, no. 5, pp. 1289–1299, 2012.

[73] N. Nosaka, D. Martinon, D. Moreira, T. R. Crother, M. Ardìti, and K. Shimada, “Autophagy protects against developing increased lung permeability and hypoxemia by down regulating inflammasome activity and IL-1β in LPS plus mechanical ventilation-induced acute lung injury,” *Frontiers in Immunology*, vol. 11, p. 207, 2020.

[74] Q. L. Wang, L. Yang, Z. L. Liu et al., “Sirtrin 6 regulates macrophage polarization to alleviate sepsis-induced acute respiratory distress syndrome via dual mechanisms dependent on and independent of autophagy,” *Cytotherapy*, vol. 24, no. 2, pp. 149–160, 2022.

[75] X. Wei, X. Yi, H. Lv et al., “MicroRNA-377-3p released by mesenchymal stem cell exosomes ameliorates lipopolysaccharide-induced acute lung injury by targeting RPTOR to induce autophagy,” *Cell Death & Disease*, vol. 11, no. 8, p. 657, 2020.

[76] B. Wang, Y. Gong, B. Ying, and B. Cheng, “Relation between red cell distribution width and mortality in critically ill patients with acute respiratory distress syndrome,” *BioMed Research International*, vol. 2019, Article ID 1942078, 8 pages, 2019.

[77] H. Wang, J. Huang, W. Liao et al., “Prognostic value of the red cell distribution width in patients with sepsis-induced acute respiratory distress syndrome: a retrospective cohort study,” *Disease Markers*, 2021, Article ID 5543822, 8 pages, 2021.

[78] S. Artavanis-Tsakonas, M. D. Rand, and R. J. Lake, “Notch signaling: cell fate control and signal integration in development,” *Science*, vol. 284, no. 5415, pp. 770–776, 1999.

[79] F. Radtke, N. Fasnacht, and H. R. Macdonald, “Notch signaling in the immune system,” *Immunity*, vol. 32, no. 1, pp. 14–27, 2010.

[80] W. Chen, Y. Liu, J. Chen et al., “The Notch signaling pathway regulates macrophage polarization in liver diseases,” *International Immunopharmacology*, vol. 99, article 107938, 2021.

[81] F. Allen and I. Maillard, “Therapeutic targeting of Notch signaling: from cancer to inflammatory disorders,” *Frontiers in Cell and Development Biology*, vol. 9, article 649205, 2021.

[82] K. Xu, N. Moghal, and S. E. Egan, “Notch signaling in lung development and disease,” *Advances in Experimental Medicine and Biology*, vol. 727, pp. 89–98, 2012.

[83] S. Sahoo, Y. Li, D. de Jesus et al., “Notch 2 suppression mimicking changes in human pulmonary hypertension modulates Notch 1 and promotes endothelial cell proliferation,” *American Journal of Physiology: Heart and Circulatory Physiology*, vol. 321, no. 3, pp. H542–h557, 2021.

[84] G. Ali, I. Di Stefano, A. M. Foma et al., “Prevalence of Delta-like protein 3 in a consecutive series of surgically resected lung neuroendocrine neoplasms,” *Frontiers in Oncology*, vol. 11, article 729765, 2021.

[85] Z. Wang, M. Lin, L. He, H. Qi, J. Shen, and K. Ying, “Exosomal Inc RNA SCIRT/mi R-665 transferring promotes lung cancer cell metastasis through the inhibition of HEYL,” *Journal of Oncology*, vol. 2021, Article ID 9813773, 13 pages, 2021.

[86] B. Xue, C. H. Chuang, H. M. Prosser et al., “miR-200 deficiency promotes lung cancer metastasis by activating Notch
signaling in cancer-associated fibroblasts,” Genes & Development, vol. 35, no. 15-16, pp. 1109–1122, 2021.

[87] L. Liu, T. Tao, S. Liu et al., “An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness,” Nature Communications, vol. 12, no. 1, p. 2693, 2021.

[88] F. Zhang, Y. Sang, D. Chen et al., “M2 macrophage-derived exosomal long non-coding RNA AGAP2-AS1 enhances radiotherapy immunity in lung cancer by reducing microRNA-296 and elevating NOTCH2,” Cell Death & Disease, vol. 12, no. 5, p. 467, 2021.

[89] Z. Zhang, Y. Gu, X. Su et al., “Co-occurring alteration of NOTCH and DDR pathways serves as novel predictor to efficacious immunotherapy in NSCLC,” Frontiers in Oncology, vol. 11, article 659321, 2021.

[90] J. Y. Xu, W. Chang, Q. Sun, F. Peng, and Y. Yang, “Pulmonary midkine inhibition ameliorates sepsis induced lung injury,” Journal of Translational Medicine, vol. 19, no. 1, p. 91, 2021.

[91] X. Bai, J. Li, L. Li et al., “Extracellular vesicles from adipose tissue-derived stem cells affect Notch-miR148a-3p axis to regulate polarization of macrophages and alleviate sepsis in mice,” Frontiers in Immunology, vol. 11, p. 1391, 2020.

[92] X. Bai, T. He, Y. Liu et al., “Acetylation-dependent regulation of Notch signaling in macrophages by SIRT1 affects sepsis development,” Frontiers in Immunology, vol. 9, p. 762, 2018.

[93] E. Keewan, S. Beg, and S. A. Naser, “Anti-TNF-α agents modulate SARS-CoV-2 receptors and increase the risk of infection through Notch-1 signaling,” Frontiers in Immunology, vol. 12, article 641295, 2021.

[94] Z. Lu, S. Meng, W. Chang et al., “Mesenchymal stem cells activate Notch signaling to induce regulatory dendritic cells in LPS-induced acute lung injury,” Journal of Translational Medicine, vol. 18, no. 1, p. 241, 2020.

[95] X. Li, Y. Dong, H. Yin, Z. Qi, D. Wang, and S. Ren, “Mesenchymal stem cells induced regulatory dendritic cells from hemopoietic progenitor cells through Notch pathway and TGF-β synergistically,” Immunology Letters, vol. 222, pp. 49–57, 2020.

[96] P. Cheng, Y. Nefedova, C. A. Corzo, and D. I. Gabrilovich, “Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands,” Blood, vol. 109, no. 2, pp. 507–515, 2007.

[97] H. Kiyokawa and M. Morimoto, “Notch signaling in the mammalian respiratory system, specifically the trachea and lungs, in development, homeostasis, regeneration, and disease,” Development, Growth & Differentiation, vol. 62, no. 1, pp. 67–79, 2020.

[98] L. C. Post, M. Ternet, and B. L. Hogan, “Notch/Delta expression in the developing mouse lung,” Mechanisms of Development, vol. 98, no. 1-2, pp. 95–98, 2000.

[99] Y. Xing, A. Li, Z. Borok, C. Li, and P. Minoo, “NOTCH1 is required for regeneration of Clara cells during repair of airway injury,” Stem Cells, vol. 30, no. 5, pp. 946–955, 2012.

[100] X. Liu, X. Zhu, G. Zhu, C. Wang, R. Gao, and J. Ma, “Effects of different ligands in the Notch signaling pathway on the proliferation and transdifferentiation of primary type II alveolar epithelial cells,” Frontiers in Pediatrics, vol. 8, p. 452, 2020.